Related Experiment Video
Updated: Mar 7, 2026
08:41
Carotid Artery Infusions for Pharmacokinetic and Pharmacodynamic Analysis of Taxanes in Mice
Published on: October 27, 2014
24.1K
Clopidogrel-Paclitaxel Drug-Drug Interaction: A Pharmacoepidemiologic Study
K Agergaard1, M Mau-Sørensen2, T B Stage1,3
1Clinical Pharmacology and Pharmacy, Department of Public Health, University of Southern Denmark, Odense, Denmark.
Clinical Pharmacology and Therapeutics
|February 23, 2017
Summary
Clopidogrel use increases the risk of severe neuropathy in patients receiving high-dose paclitaxel. This drug interaction, involving cytochrome P450 2C8 (CYP2C8), highlights potential safety concerns in cancer treatment.
Area of Science:
- Pharmacology
- Clinical Oncology
- Drug Interactions
Background:
- Paclitaxel is primarily metabolized by CYP2C8 in the liver.
- Clopidogrel's active metabolite, acyl-β-D-glucuronide, is a potent inhibitor of CYP2C8.
- Potential for drug-drug interactions impacting paclitaxel toxicity exists.
Purpose of the Study:
- To investigate the clinical relevance of the interaction between clopidogrel and paclitaxel.
- To assess the risk of peripheral sensory neuropathy associated with concomitant use of these drugs.
Main Methods:
- Retrospective cohort study of 48 patients treated with clopidogrel and paclitaxel.
- Comparison with 88 age- and sex-matched controls receiving paclitaxel and aspirin.
- Evaluation of severe neuropathy from medical charts.
Main Results:
- 35% of patients developed severe neuropathy by 1,500 mg cumulative paclitaxel dose.
- Overall hazard ratio for severe neuropathy with clopidogrel was 1.7 (95% CI, 0.9-3.0).
- Hazard ratio increased to 2.3 (95% CI, 1.1-4.5) in patients on high-dose paclitaxel regimens.
Conclusions:
- Clopidogrel is associated with a clinically significant increased risk of neuropathy in patients receiving high-dose paclitaxel.
- This interaction warrants consideration in clinical practice to optimize patient safety.
- Further research may be needed to explore management strategies for this interaction.
Related Concept Videos
01:25Pharmacokinetics: Drug–Drug Interactions
569
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
569
01:30Drug toxicity: Drug–Drug Interaction
148
Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
148
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
76
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
76
01:26Pharmacokinetics: Drug–Food and Drug–Viral Interactions
396
A drug interaction occurs when the concurrent use of another drug, food, or an external substance alters the pharmacological activity of a drug. This interaction can modify the action of the original drug, affecting its effectiveness and safety.Drug–food interactions are significant as they impact drug absorption, metabolism, and excretion. For example, grapefruit juice is a well-known disruptor of drug metabolism. It inhibits the cytochrome P450 3A4 enzyme, crucial for the metabolism of...
396
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.4K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.4K
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
319
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
319